Tirzepatide | Weight Loss

Experience the power of Tirzepatide, the breakthrough weight loss peptide that can unlock your journey to a healthier you.

• Accelerated Weight Loss
• Enhanced Metabolic Control
• Effective Appetite Suppression

Tirzepatide is a powerful weight loss peptide that targets multiple biological pathways in your body to provide comprehensive benefits. Extensive research has shown that Tirzepatide can significantly reduce body weight, improve metabolic markers, and better control over appetite. Its unique mechanism of action makes it a promising option for those struggling with weight management and related conditions.

Am I a good candidate?

If you have struggled with weight loss and are looking for a powerful solution, Tirzepatide might be the catalyst you need. It can be particularly suitable for individuals who have difficulty managing their blood sugar levels or who experience intense food cravings.

What to Expect:

Consultation:

• Upon ordering, you'll receive a link to book your provider consult for a discussion about your prescription and how it works.
• Your peptide will only ship after the consult is completed.

Shipping:

• Your package will arrive discreetly packaged, including one vial of peptide, syringes, and medical supplies.
• Peptides are shipped from a US Pharmacy, taking 1-4 weeks for processing and shipping cold on ice.

Dosing:

• Dosage is prescribed by our providers once you're cleared and based on your unique needs. Tirzepatide is injected once per week subcutaneously.
• Self-administering peptides is quick and easy. Refer to the instructional video or instructions tab in your package for help.

Side effects:

• Peptides are well tolerated with minimal side effects in our experience but beware of potential complications from improper injection.

Please note:

• Peptides have limited availability, and shipping is subject to state regulations.

Citations:

• Frias, J. P., Nauck, M. A., Van J, A. D., Jódar, E., Embalo, C., Jaghutriz, B. A., ... & Doupis, J. (2021). Tirzepatide versus placebo or semaglutide once weekly in patients with type 2 diabetes [(SURPASS-5)]: a randomised, controlled, double-blind, phase 3 trial. The Lancet, 398(10303), 143-155.
• Frias, J. P., Nauck, M. A., Van J, A. D., Jódar, E., Jaghutriz, B. A., Embalo, C., ... & Inuduka, Y. (2021). Efficacy and safety of once-weekly tirzepatide versus insulin glargine in patients with type 2 diabetes on metformin with or without sulfonylureas (SURPASS-3): a randomised, open-label, phase 3a trial. The Lancet, 398(10307), 193-202.
• Rosenstock, J., Wysham, C. H., Frías, J. P., Kaneko, S., Kuang, Y., Fung, A., ... & Kumar, H. (2021). Efficacy and safety of once-weekly tirzepatide versus placebo in patients with type 2 diabetes on background metformin monotherapy: a 52-week, phase 3 randomised controlled trial (SURPASS-2). The Lancet, 398(10307), 133-142.